Previous 10 | Next 10 |
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announ...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announ...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announ...
2023-03-20 23:57:05 ET Lantern Pharma Inc. (LTRN) Q4 2022 Results Earnings Conference Call March 21, 2023, 04:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Fin...
2023-03-20 22:37:41 ET The following slide deck was published by Lantern Pharma Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Lantern Pharma Inc. 2022 Q4 - Results - Earnings Call Presentation
2023-03-20 16:04:39 ET Lantern Pharma press release ( NASDAQ: LTRN ): Q4 GAAP EPS of -$0.31 beats by $0.16 . Cash, cash equivalents, and marketable securities were $55.2 million as of December 31, 2022, compared to $70.7 million as of December 31, 2021. The quarterly a...
The Harmonic™ clinical trial, a Phase 2 study in never-smoker patients with non-small lung cancer, has activated 5 clinical trial sites, across 12 locations, and anticipates multiple additional sites in the US during the 1 st half of 2023; first enrolled patients are anticipated for Q2...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announ...
Webcast to be held Monday, Mar. 20, 4:30 p.m. ET, register here , or at the link below. Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform t...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that neither L...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...